Relationship between weight change and glycaemic control in patients with type 2 diabetes receiving once-weekly dulaglutide treatment

• Type of Material: Article
• Authors: Guillermo Umpierrez, Emory University; Kevin M. Pantalone, Cleveland Clinic; Anita Y.M. Kwan, Lilly USA, LLC; Alan G. Zimmermann, Eli Lilly and Company; Nan Zhang, Eli Lilly and Company; Laura Fernández Lando, Lilly USA, LLC
• Language: English
• Date: 2016-06-01
• Publisher: Wiley: 12 months
• Publication Version: Final Published Version
• Copyright Statement: © 2016 The Authors.
• License: Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1111/dom.12660
• Title of Journal or Parent Work: Diabetes, Obesity and Metabolism
• ISSN: 1462-8902
• Volume: 18
• Issue: 6
• Start Page: 615
• End Page: 622
• Grant/Funding Information: This work was sponsored by Eli Lilly and Company.
• Keywords: type 2 diabetes; LIRAGLUTIDE; OPEN-LABEL; EFFICACY; SAFETY; dulaglutide; CENTERED APPROACH; TRIAL; Life Sciences & Biomedicine; GLP-1 analogueincretin therapy; CARDIOVASCULAR RISK; incretin therapy; NON-INFERIORITY; ASSOCIATION; Endocrinology & Metabolism; Science & Technology; MANAGEMENT
• Research Categories: Health Sciences, Pharmacology; Health Sciences, General

Abstract

Aim: To assess the relationship between weight change and glycated haemoglobin (HbA1c) change in dulaglutide‐treated patients by analysing data from six head‐to‐head phase III AWARD clinical trials. Methods: At 26 weeks, the relationship between weight and HbA1c was analysed in each trial rather than by pooling data because of differences in design and background therapy. The effect of baseline characteristics was also evaluated with regard to weight and HbA1c response. Results: Across the studies, 87–97% and 83–95% of patients treated with dulaglutide 1.5 and 0.75 mg, respectively, had reductions in HbA1c levels, while 57–88% and 43–84% of patients treated with dulaglutide 1.5 and 0.75 mg, respectively, experienced weight loss. The majority (55–83%) of patients receiving dulaglutide 1.5 mg experienced weight loss and HbA1c reductions, while 41–79% of patients in the dulaglutide 0.75 mg arm lost weight and had reductions in HbA1c level. A weak and inconsistent correlation was observed between the changes in weight and HbA1c (range from −0.223 to 0.267) in patients treated with dulaglutide. The baseline characteristics of gender, age, duration of diabetes, HbA1c, body weight and BMI were not related to different combinations of weight and HbA1c responses. Conclusions: Dulaglutide is an effective treatment option across the type 2 diabetes treatment spectrum. Dulaglutide showed dose‐dependent effects on both weight loss and HbA1c reduction. These effects had a weak correlation and appeared to be independent.